연구동향 분석

REVIEW : Treatment of Drug Susceptible Pulmonary Tuberculosis

( Hong Joon Shin ) ( Yong Soo Kwon ) 2015년

논문상세정보
인용/피인용
' REVIEW : Treatment of Drug Susceptible Pulmonary Tuberculosis' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • antitubercular agents
  • combination therapy
  • drugrelatedsideeffectsandadversereactions
  • fluoroquinolones
  • tuberculosis
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
447 0

0.0%

' REVIEW : Treatment of Drug Susceptible Pulmonary Tuberculosis' 의 참고문헌

  • 한국에서의 결핵현황
    김희진 대한내과학회지 82 (3) : 257 ~ 262 [2012]
  • USPHS Tuberculosis Short-Course Chemotherapy Trial 21 : effectiveness, toxicity, and acceptability. The report of final results
    Combs DL. Ann Intern Med 112 : 397 ~ 406 [1990]
  • Tuberculosis and nontuberculosis mycobacterial infections
    Schlossberg D. ASM Press [2011]
  • Tuberculosis Treatment in Patients with Comorbidities
    강영애 Tuberculosis and Respiratory Diseases 76 (6) : 257 ~ 260 [2014]
  • Tuberculosis : clinical trials and new drug regimens
    Kwon YS. Curr Opin Pulm Med 20 : 280 ~ 286 [2014]
  • Tuberculosis
    Zumla A. N Engl J Med 368 : 745 ~ 755 [2013]
  • Treatment of tuberculosis : guidelines for national programmes. 4th ed
  • The seventh nationwide tuberculosis prevalence survey in Korea, 1995
    Hong YP. Int J Tuberc Lung Dis 2 : 27 ~ 36 [1998]
  • The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis
    Blomberg B. Bull World Health Organ 79 : 61 ~ 68 [2001]
  • The National Status of Tuberculosis Using Nationwide Medical Records Survey of Patients with Tuberculosis in Korea
    Yoon-Sung Park Tuberculosis and Respiratory Diseases 73 (1) : 48 ~ 55 [2012]
  • Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion
    Johnson JL. Am J Respir Crit Care Med 180 : 558 ~ 563 [2009]
  • Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen
    Jo KW. Respir Med 108 : 654 ~ 659 [2014]
  • Risk Factors for Death during Pulmonary Tuberculosis Treatment in Korea: A Multicenter Retrospective Cohort Study
    권용수 Journal of Korean Medical Science 29 (9) : 1226 ~ 1231 [2014]
  • Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis
    Nunn AJ. Int J Tuberc Lung Dis 18 : 1252 ~ 1254 [2014]
  • Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation
    Milan-Segovia RC. Int J Tuberc Lung Dis 14 : 1454 ~ 1460 [2010]
  • Pulmonary tuberculosis in children : evaluation with CT
    Kim WS. AJR Am J Roentgenol 168 : 1005 ~ 1009 [1997]
  • Pulmonary tuberculosis : CT findings--early active disease and sequential change with antituberculous therapy
    Im JG. Radiology 186 : 653 ~ 660 [1993]
  • Pleural tuberculosis evaluated by computed tomography
    Hulnick DH. Radiology 149 : 759 ~ 765 [1983]
  • Korean guidelines for tuberculosis. 2nd ed
    Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention [2014]
  • Intrathoracic adenopathy associated with pulmonary tuberculosis in patients with human immunodeficiency virus infection
    Pastores SM. Chest 103 : 1433 ~ 1437 [1993]
  • Increased Tuberculosis Burden Due to Demographic Transition in Korea from 2001 to 2010
    박영길 Tuberculosis and Respiratory Diseases 74 (3) : 104 ~ 110 [2013]
  • Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy
    Lee BH. Chest 127 : 1304 ~ 1311 [2005]
  • High-dose rifapentine with moxifloxacin for pulmonary tuberculosis
    Jindani A. N Engl J Med 371 : 1599 ~ 1608 [2014]
  • High resolution chest CT in patients with pulmonary tuberculosis : characteristic findings before and after antituberculous therapy
    Lee JJ. Eur J Radiol 67 : 100 ~ 104 [2008]
  • High resolution CT findings in miliary lung disease
    McGuinness G. J Comput Assist Tomogr 16 : 384 ~ 390 [1992]
  • Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis
    Shin HJ. Int J Tuberc Lung Dis 18 : 347 ~ 351 [2014]
  • Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy
    Kwon YS. Chest 131 : 803 ~ 808 [2007]
  • Global tuberculosis report 2014
  • Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis
    Gillespie SH. N Engl J Med 371 : 1577 ~ 1587 [2014]
  • Fixed-dose combination antituberculosis therapy : a systematic review and meta-analysis
    Albanna AS. Eur Respir J 42 : 721 ~ 732 [2013]
  • Enhancing patient compliance with tuberculosis therapy
    Cuneo WD. Clin Chest Med 10 : 375 ~ 380 [1989]
  • Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis : the Study C randomized controlled trial
    Lienhardt C. JAMA 305 : 1415 ~ 1423 [2011]
  • Definitions and reporting framework for tuberculosis, 2013 revision: WHO/HTM/TB/2013.2
  • Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment
    Seon HJ. Int J Tuberc Lung Dis 18 : 341 ~ 346 [2014]
  • Annual report on the notified tuberculosis patients in Korea 2012
  • Annual report of deaths by cause 2012
  • An official ATS statement : hepatotoxicity of antituberculosis therapy
    Saukkonen JJ. Am J Respir Crit Care Med 174 : 935 ~ 952 [2006]
  • American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America : treatment of tuberculosis
    Blumberg HM. Am J Respir Crit Care Med 167 : 603 ~ 662 [2003]
  • A nested case-control study on treatment-related risk factors for early relapse of tuberculosis
    Chang KC. Am J Respir Crit Care Med 170 : 1124 ~ 1130 [2004]
  • A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization
  • A four-month gatifloxacin-containing regimen for treating tuberculosis
    Merle CS. N Engl J Med 371 : 1588 ~ 1598 [2014]